Literature DB >> 31571137

A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis.

Sandjar Djalalov1,2,3, Jaclyn Beca4, Emmanuel M Ewara5, Jeffrey S Hoch6.   

Abstract

OBJECTIVES: The aim of this study was to use Microsoft Excel spreadsheet software to fit parametric survival distributions. We also explain the differences between individual patient data (IPD) and survival data reconstructed in Excel and SAS.
METHODS: Three sets of patient data on overall survival were compared using different methods: 'original' IPD, 'reconstructed SAS', and 'reconstructed Excel'. The best-fit distribution was selected using visual observation, supported by linear plots of predicted probabilities, goodness-of-fit coefficients, and the sum of squared error of prediction. Outcomes included the incremental cost-effectiveness ratio (ICER), incremental net benefit (INB), incremental cost, and life-years gained over short-term and lifetime horizons. These were compared for different data sets.
RESULTS: In this example, log-normal, log-logistic, and Weibull distributions showed best-fit with the visual tests and goodness-of-fit statistics. Weibull and exponential distributions showed significant differences compared with IPD data. Data on short-term (5 years) time horizons produced by different data re-creation methods showed closeness with data reconstructed from SAS. The ICER and INB results were dependent on the time horizon and selected parametric distribution from the model.
CONCLUSIONS: Different approaches used in fitting parametric survival distributions yielded predicted probabilities that substantially differed from those using original IPD. Our study highlights the importance of following guidelines for economic evaluations with a systematic approach to parametric survival analysis techniques in order to select best fitting parametric survival distributions.

Entities:  

Year:  2019        PMID: 31571137     DOI: 10.1007/s40273-019-00830-4

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  11 in total

1.  Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial.

Authors:  Vakaramoko Diaby; Georges Adunlin; Alberto J Montero
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

2.  The "hazards" of extrapolating survival curves.

Authors:  Charlotte Davies; Andrew Briggs; Paula Lorgelly; Göran Garellick; Henrik Malchau
Journal:  Med Decis Making       Date:  2013-03-03       Impact factor: 2.583

Review 3.  Overview of parametric survival analysis for health-economic applications.

Authors:  K Jack Ishak; Noemi Kreif; Agnes Benedict; Noemi Muszbek
Journal:  Pharmacoeconomics       Date:  2013-08       Impact factor: 4.981

4.  Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.

Authors:  Linda Lee; Michael Crump; Sara Khor; Jeffrey S Hoch; Jin Luo; Karen Bremner; Murray Krahn; David C Hodgson
Journal:  Br J Haematol       Date:  2012-06-05       Impact factor: 6.998

5.  Modelling survival in hepatocellular carcinoma.

Authors:  Noemi Muszbek; Noemi Kreif; Adriana Valderrama; Agnes Benedict; Jack Ishak; Paul Ross
Journal:  Curr Med Res Opin       Date:  2012-06-26       Impact factor: 2.580

6.  Understanding survival analysis: Kaplan-Meier estimate.

Authors:  Manish Kumar Goel; Pardeep Khanna; Jugal Kishore
Journal:  Int J Ayurveda Res       Date:  2010-10

7.  Improved curve fits to summary survival data: application to economic evaluation of health technologies.

Authors:  Martin W Hoyle; William Henley
Journal:  BMC Med Res Methodol       Date:  2011-10-10       Impact factor: 4.615

8.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.

Authors:  Patricia Guyot; A E Ades; Mario J N M Ouwens; Nicky J Welton
Journal:  BMC Med Res Methodol       Date:  2012-02-01       Impact factor: 4.615

9.  Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis.

Authors:  Sara Khor; Jaclyn Beca; Murray Krahn; David Hodgson; Linda Lee; Michael Crump; Karen E Bremner; Jin Luo; Muhammad Mamdani; Chaim M Bell; Carol Sawka; Scott Gavura; Terrence Sullivan; Maureen Trudeau; Stuart Peacock; Jeffrey S Hoch
Journal:  BMC Cancer       Date:  2014-08-12       Impact factor: 4.430

10.  A review and comparison of methods for recreating individual patient data from published Kaplan-Meier survival curves for economic evaluations: a simulation study.

Authors:  Xiaomin Wan; Liubao Peng; Yuanjian Li
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

View more
  2 in total

1.  Cost-effectiveness of camrelizumab versus chemotherapy for the treatment of advanced or metastatic esophageal squamous cell carcinoma.

Authors:  Lizong Li; Xuemei Liu; Jing Huang; Yi Liu; Lin Huang; Yufei Feng
Journal:  J Gastrointest Oncol       Date:  2022-02

2.  Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.

Authors:  Meng-Meng Teng; Si-Ying Chen; Bo Yang; Yan Wang; Rui-Ying Han; Meng-Na An; Ya-Lin Dong; Hai-Sheng You
Journal:  Cancer Med       Date:  2021-08-12       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.